242
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate

, , , , , , , , , , , , & show all
Pages 2639-2644 | Received 02 Jan 2012, Accepted 08 Mar 2013, Published online: 19 Apr 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Xiaoqin Zhu, Wei Li, Jia Zhu, Huimou Chen, Jinqiu Guan, Dalei Zhou, Zijun Zhen, Feifei Sun, Junting Huang, Juan Wang, Xiaofei Sun, Suying Lu & Yizhuo Zhang. (2021) Influence of MTHFR C677T and A1298C polymorphisms on the survival of pediatric patients with non-Hodgkin lymphoma. Leukemia & Lymphoma 62:10, pages 2374-2382.
Read now
Nirmalya Roy Moulik, Archana Kumar, Suraksha Agrawal, Shally Awasthi, Abbas Ali Mahdi & Ashutosh Kumar. (2015) Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia. Leukemia & Lymphoma 56:5, pages 1379-1384.
Read now
Velia D’Angelo, Maria Ramaglia, Adriana Iannotta & Raffaele Addeo. (2014) Pharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms?. Expert Review of Hematology 7:5, pages 517-519.
Read now

Articles from other publishers (8)

Suying Lu, Xiaoqin Zhu, Wei Li, Huimou Chen, Dalei Zhou, Zijun Zhen, Feifei Sun, Junting Huang, Jia Zhu, Juan Wang, Yizhuo Zhang & Xiaofei Sun. (2021) Influence of Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism on High-Dose Methotrexate-Related Toxicities in Pediatric Non-Hodgkin Lymphoma Patients. Frontiers in Oncology 11.
Crossref
Andrea Giletti & Patricia Esperon. (2018) Genetic markers in methotrexate treatments. The Pharmacogenomics Journal 18:6, pages 689-703.
Crossref
Ali Amin Asnafi, Niloofar Farshchi, Abbas Khosravi, Neda Ketabchi, Masumeh Maleki Behzad & Saeid Shahrabi. (2018) Significance of genetic polymorphisms in hematological malignancies: implications of risk factors for prognosis and relapse. memo - Magazine of European Medical Oncology 11:4, pages 330-344.
Crossref
C Zhu, Y W Liu, S Z Wang, X L Li, X L Nie, X T Yu, L B Zhao & X L Wang. (2017) Associations between the C677T and A1298C polymorphisms of MTHFR and the toxicity of methotrexate in childhood malignancies: a meta-analysis. The Pharmacogenomics Journal 18:3, pages 450-459.
Crossref
Rachel Conyers, Subalatha Devaraja & David Elliott. (2018) Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients. Pediatric Blood & Cancer 65:4, pages e26937.
Crossref
Michael J. Tidman & Catherine H. Smith. 2016. Rook's Textbook of Dermatology, Ninth Edition. Rook's Textbook of Dermatology, Ninth Edition 1 51 .
Vid Mlakar, Patricia Huezo-Diaz Curtis, Chakradhara Satyanarayana Uppugunduri, Maja Krajinovic & Marc Ansari. (2016) Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use. International Journal of Molecular Sciences 17:9, pages 1502.
Crossref
Jing He, Xiao-Yu Liao, Jin-Hong Zhu, Wen-Qiong Xue, Guo-Ping Shen, Shao-Yi Huang, Wei Chen & Wei-Hua Jia. (2014) Association of MTHFR C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: Evidence from a meta-analysis. Scientific Reports 4:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.